Aurinia Q2 net product revenue $55M (+34% YoY); net income $0.7M, cash flow positive

Aurinia Pharmaceuticals Inc.

2024-Q2 EPS reported -$0.07 revenue$107,495,000

Net product revenue $55.0M, up 34% YoY; total net revenue $57.2M (+38% YoY).
Net income $0.7M vs loss of $11.5M in Q2 2023; generated $15.8M free cash flow.
Narrows 2024 net product revenue guidance to $210-220M from $200-220M.
2,336 patients on LUPKYNIS (+22% YoY); AUR200 Phase 1 SAD starts Q3 2024.
Cash $330.7M; repurchased 3.4M shares for $18.6M YTD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.